MetaCap

Contineum Therapeutics Inc. Class A (CTNM)

NASDAQ: CTNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.68-0.36 (-3.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CTNM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$340.83M
EPS (TTM)
-$1.77
52-week range
6.73 – 17.79
Day range
8.50 – 9.09
Volume / Avg
369.21K / 776.03K
Beta
—

52-week range

$6.73$17.79

CTNM stock today

On Nov 20, CTNM ended the session at $8.68, shedding $0.36 (3.98%), versus the S&P 500's 3.70% decline. Trading was light, with 369.21K shares changing hands, about 48% of the average daily volume. At this level, CTNM sits near the bottom of its 52-week range of $6.73 to $17.79: 51.2% below the high, set on Sep 3, 2026 and 29.1% above the low.

CTNM is down 24.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.7%. Contineum Therapeutics has posted a net loss over the last twelve months (EPS of -$1.77), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Contineum Therapeutics

Company profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Carmine N. Stengone MBA, MS
Headquarters
San Diego, CA
Employees
51
IPO year
2024

Financial highlights

Full financials

Contineum Therapeutics reported a net loss of $60.0 million, compared with a loss of $42.3 million a year earlier. Diluted earnings per share came in at -$2.17.

Contineum Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue—$0$50.00M
Growth—-100.00%—
Net income$-59.98M$-42.26M$22.72M
EPS (diluted)$-2.17$-2.18$0.08

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$21.43+146.89%

  • Strong buy 1
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $14.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.49 vs $-0.45
Surprise
-8.89%

CTNM news

All CTNM news

Contineum Therapeutics peers

Health Care sector
CTNM peer companies
CompanyPrice% ChgMarket capCompare
MPLTMapLight Therapeutics Inc.5.94-7.48%$330.12Mvs CTNM
INOInovio Pharmaceuticals Inc.1.76+2.92%$329.66Mvs CTNM
LRMRLarimar Therapeutics Inc.3.14-2.48%$328.55Mvs CTNM
PEPGPepGen Inc.3.78-3.82%$356.31Mvs CTNM
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs CTNM
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs CTNM
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs CTNM
PHATPhathom Pharmaceuticals Inc.4.66-8.27%$378.82Mvs CTNM

Indexes, lists and sector

Contineum Therapeutics stock FAQ

What is Contineum Therapeutics's stock price today?

CTNM last traded at $8.68 as of Nov 20, 4:00 PM EST, down 3.98% on the day. Prices are delayed at least 15 minutes.

Who is Contineum Therapeutics's CEO?

Mr. Carmine N. Stengone MBA, MS is the chief executive officer of Contineum Therapeutics Inc. Class A, which has about 51 employees.

What is the CTNM 52-week high?

The 52-week high for CTNM is $17.79 and the 52-week low is $6.73. The stock is currently 51.2% below its high.

Compare CTNM